Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit

Zymeworks Inc. ZYME on Tuesday decided to voluntarily discontinue clinical development of ZW171, a T-cell engager designed to target gynecological, thoracic, and digestive system cancers.ZW171 is designed to address cancers driven by mesothelin, a well-recognized but historically challenging target.The decision to discontinue clinical development of ZW171 was based on completion of the planned cohorts of the dose escalation portion of the Phase 1 trial of ZW171 in patients with ovarian cancer and non-small ...